BGLC - BioNexus Gene Lab Corp. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BGLC

BIONEXUS GENE LAB CORP.

NASDAQ

$1.55

▲ UP 3.33% (0.05)

KEY STATISTICS

Market Cap$3.75 M

52w High$6.10

52w Low$1.07

Dividend Yield—

Frequency—

P/E-1.22

Volume2.58K

Shares Out.2.42M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Su-Leng Tan

COMPENSATION 2026

Salary$0

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$0

ABOUT

SECTOR

Industrials

WENT PUBLIC

January 8, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

SPLIT RECORD

DATE	TYPE	RATIO
2025-04-07	Reverse	1:10
2023-07-20	Reverse	1:12

PRICE

$1.55 ▲ UP 3.33% (+$0.05)

OVERLAYS

About BioNexus Gene Lab Corp.

https://www.bionexusgenelab.com ↗

BioNexus Gene Lab Corp. engages in wholesale chemical raw materials across Southeast Asia and develops non-invasive liquid biopsy tests for early biomarker detection, based in Kuala Lumpur since 2017.

INDUSTRY

Industrial - Distribution

A SERVICE BIONEXUS GENE LAB CORP. IS KNOWN FOR

VitaGuard™ MRD platform

VitaGuard™ is a liquid biopsy platform by BioNexus Gene Lab Corp. for early cancer recurrence detection via blood tests, aiming to make precision oncology diagnostics more accessible and affordable across Southeast Asia.

COMPETITORS

COMPETITOR

Revenue by Products

Icon	PRODUCT	Q2-2025	Q3-2025
	Product And Service	$2.26M	$2.54M ▲

Revenue by Geography

REGION	Q3-2025	Q4-2025	Q1-2026	Q2-2026
Myanmar	—	—	—	$99K
INDONESIA	$31.36K	$83.51K ▲	—	—
MALAYSIA	$1.78M	$2.22M ▲	$22.84K ▼	—
SOUTH AFRICA	—	—	—	$12.44K
SRI LANKA	$193.05K	$4.12K ▼	—	—
SINGAPORE	$108.25K	$664 ▼	—	—